导师姓名：李德山
性别：男
人气指数：374

所属院校：东北农业大学
所属院系：生命科学学院
职称：教授
导师类型：硕导
招生专业：生物化学与分子生物学


通讯方式 :
办公电话：**
电子邮件：deshanli@163.com


科研工作 :
1.东北农业大学治疗2型糖尿病新基因药物脂糖素开发项目（省发改委），1000万2.猪流行性腹泻、鸡传染性法氏囊和鸭病毒性肝炎Ⅰ型+Ⅲ型重组治疗抗体（CHO细胞源）的研制，160万3.万级洁净实验室（中试车间）和配套设备开发项目，200万4.高效生产治疗结直肠癌的西妥昔单抗工程细胞株构建、筛选与生产工艺的建立（省攻关），50万5.国家自然基金东北农业大学生物学理科基地科研训练及科研能力提高项目，10万6.黑龙江省科技成果转化瓶颈的对策研究（省攻关），7万7.成纤维细胞生长因子（FGF）-21中试工艺研究（教育厅），10万8.脂糖素（FGF-21）中试工艺的研究（哈市科技局），7万。近五年代表性著作、论文：1.FangmingKan,GuipingRen,MoGuo,JianyingQi,YuZhang,YangHan,YakunZhang,DeshanLi.Constructionofananti-IL-1βscfvandTNFRIfusionproteinanditstherapeuticeffectonRAmicemodel.CurrentPharmaceuticalBiotechnology,2013,14（12）：1048-1061（Factor：2.69）2.YeX,QiJ,SunG,RenG,ZhuS,WuY,YuD,ZhaoJ,LiuM,LiD.EnhancementofthepharmacologicalefficacyofFGF-21bygeneticmodificationandPEGylation.CurrPharmBiotechnol.201314(15):1287-1298.（Factor：2.69）3.ShenglongZhu,LeiMa,YunzhouWu,XianlongYe,TianyuanZhang,QingyangZhang,LubnaMuhiRasoul,YunyeLiu,MoGuo,BingZhou,GuipingRen,andDeshanLi.FGF21treatmentamelioratesalcoholicfattyliverthroughactivationofAMPK-SIRT1pathway.ActaBiochimBiophysSin.201446(12):1041-1048.（Factor：2.089）4.XianlongYe,JianyingQi,GuipingRen,PengfeiXu,YunzhouWu,ShenglongZhu,DanYu,ShujieLi,QiangWu,RasoolLubnaMuhi,DeshanLi.Long-lastinganti-diabeticefficacyofPEGylatedFGF-21andliraglutideintreatmentoftype2diabeticmice.Endocrine,2015,49（3）：683–692(ImpactFactor:3.527)5.YinhangYu,SimingLi,YaonanLiu,GuiyouTian,QingyanYuan,FuliangBai,WenfeiWang,ZhiyiZhang,GuipingRen,YuZhang,DeshanLi.Fibroblastgrowthfactor21(FGF21)amelioratescollagen-inducedarthritisthroughmodulatingoxidativestressandsuppressingnuclearfactor-kappaBpathway.InternationalImmunopharmacology.2015,25(1):74-82(ImpactFactor:2.711)6.YinhangYu,FuliangBai,YaonanLiu,YongbiYang,QingyanYuan,DehuaZou,SusuQu,GuiyouTian,LiyingSong,TongZhang,SimingLi,YunYeLiu,WenfeiWang,GuipingRen,DeshanLi.Fibroblastgrowthfactor(FGF21)protectsmouseliveragainstD-galactose-inducedoxidativestressandapoptosisviaactivatingNrf2andPI3K/Aktpathways.MolCellBiochem.2015,403(1-2):287-299(ImpactFactor:2.388)7.PengfeiXu,XianlongYe,YingjieZhang,QingyanYuan,MingyaoLiu,QiangWu,GuipingRen,DeshanLi.Long-actinghypoglycemiceffectsofPEGylatedFGF21andinsulinglargineinmicewithtype1diabetes.JournalofDiabetesanditsComplications.2015,29(1):5-12（Factor：3.005）8.YinhangYu,FuliangBai,WenfeiWang,YaonanLiu,QingyanYuan,SusuQu,TongZhang,GuiyouTian,SimingLi,DeshanLi,GuipingRen.Fibroblastgrowthfactor21protectsmousebrainagainstD-galactoseinducedagingviasuppressionofoxidativestressresponseandadvancedglycationendproductsformation.Pharmacology,BiochemistryandBehavior,2015,133:122-13(ImpactFactor:2.82)9.PengfeiXu,YingjieZhang,WenfeiWang,QingyanYuan,ZhihangLiu,LubnaMuhiRasoul,QiangWu,MingyaoLiu,XianlongYe,DeshanLi,GuipingRen.Long-TermAdministrationofFibroblastGrowthFactor21PreventsChemically-InducedHepatocarcinogenesisinMice.DigestiveDiseasesandSciences,2015,60（10）:3032-3043(ImpactFactor:2.613)10.YinBai,YanminChen,NanZhang,XiaochenGuo,JingzhuangZhao,FuxiangWang,PengfeiXu,QingyanYuan,JianyingQi,WenfeiWang,DeshanLiandGuipingRen.IsolationoftheneutralizationScFvsagainstHBVinfectionfromtheimmunizedpopulation.CurrentPharmaceuticalBiotechnology,2015,16(10):902-910.(ImpactFactor:1.95)11.GuipingRen,GuiyouTian,YunyeLiu,JinjiaoHe,XinyuGao,YinhangYu,XinLiu,XuZhang,TianSun,ShuangqingLiu,JiechaoYin,andDeshanLi.RecombinantNewcastleDiseaseVirusEncodingIL-12and/orIL-2asPotentialCandidateforHepatomaCarcinomaTherapy.TechnologyinCancerResearch&Treatment(ImpactFactor:1.730)12.QiJ,KanF,YeX,GuoM,ZhangY,RenG,LiD.AbispecificantibodyagainstIL-1βandIL-17Aisbeneficialforexperimentalrheumatoidarthritis.IntImmunopharmacol.(InternationalImmunopharmacology).2012,14(4):770-778.(ImpactFactor:2.376)13.ZhangY,RenG,GuoM,YeX,ZhaoJ,XuL,QiJ,KanF,LiuM,LiD.Synergisticeffectsofinterleukin-1βandinterleukin-17Aantibodiesoncollagen-inducedarthritismousemodel.IntImmunopharmacol.(InternationalImmunopharmacology.)2013,15(2):199-205.(ImpactFactor:2.376)14.JianyingQi,XianlongYe,GuipingRen,FangmingKan,YuZhang,MoGuo,ZhiyiZhang,DeshanLi.Pharmacologicalefficacyofanti-IL-1βscFv,Fabandfull-lengthantibodiesintreatmentofrheumatoidarthritis.MolecularImmunology.2013,57,(2):59–65(factor：2.645)15.TianheLi,LimingXu,GuipingRen,ChengkaiYin,BingZhou,XianlongYe,QingcuiLi,NingLiandDeshanLi.ANeutralizationscFvAntibodyagainstIL-1βIsolatedfromaNIPA-basedBacterialDisplayLibrary.CurrentPharmaceuticalBiotechnology.2013,14(6):571-581(factor：2.69)16.ZhengLv,Tian-YuanZhang,Jie-ChaoYin,HuiWang,TianSun,Li-QunChen,Fu-LiangBai,WeiWu,Gui-PingRen,De-ShanLi.EnhancementofAnti-tumorActivityofNewcastleDiseaseVirusbytheSynergisticEffectofCytosineDeaminase.AsianPacificJournalofCancerPrevention,201314(12):7489-7496.（ImpactFactor:1.271）17.FuliangBai,HuiTian,ZeshanNiu,MingyaoLiu,GuipingRen,YinhangYu,TianSun,SimingLi,DeshanLI.Chimericanti-IL-17full-lengthmonoclonalantibodyisanovelpotentialcandidateforthetreatmentofrheumatoidarthritis.InternationalJournalofmolecularmedicine,2014,33（3）:711-721.（ImpactFactor:1.957）18.MoGuo,Li-MingXu,BingZhou,Jie-ChaoYin,Xian-LongYe,Gui-PingRen,De-ShanLi.Anchoredperiplasmicexpression(APEx)-basedbacterialdisplayforrapidandhigh-throughputscreeningofBcellepitopes.BiotechnologyLetters（BiotechnolLett）,2014,36（3）：609-616（ImpactFactor:1.853）19.YunzhouWu,ShijunYan,ZhengLv,LinChen,JingshuGeng,JinjiaoHe,QingzhongYu,JiechaoYin,GuipingRen,DeshanLi.RecombinantNewcastleDiseasevirusAnhingaStrain(NDV/Anh-EGFP)forHepatomaTherapy.TechnologyinCancerResearchandTreatment,2014,13(2):169-175.（ImpactFactor:1.943）20.FuliangBai,ZeshanNiu,HuiTian,SimingLi,ZhengLv,TianyuanZhang,GuipingRen,DeshanLi.GeneticallyengineeredNewcastlediseasevirusexpressinginterleukin2isapotentialdrugcandidateforcancerimmunotherapy.ImmunologyLetters（ImmunolLett.）2014，159(1-2):36-46.（ImpactFactor:2.337）21.ZeshanNiu,FuliangBai,TianSun,HuiTian,DanYu,JiechaoYin,SimingLi,TianheLi,HongweiCao,QingzhongYu,YunzhouWu,GuipingRen,DeshanLi.RecombinantNewcastleDiseasevirusExpressingIL15DemonstratesPromisingAntitumorEfficiencyinMelanomaModel.TechnologyinCancerResearchandTreatment,2014,online,Epubaheadprint（ImpactFactor:1.943）22.QingcuiLi,GuipingRen,LimingXu,QiuyingWang,JianyingQi,WenfeiWang,BingZhou，XiaohuiHan,CuiyuSun,QiangWu,YinhangYu,ZhongyiPeng,ShiminZheng,DeshanLi.Therapeuticefficacyofthreebispecificantibodiesoncollagen-inducedarthritismousemodel.IntImmunopharmacol.2014,21(1):119–127(ImpactFactor:2.376)23.Wen-FeiWang,Si-MingLi,Gui-PingRen,WeiZheng,Yu-JiaLu,Yin-HangYu,Wen-JuanXu,Tian-HeLi,Li-HongZhou,YanLi,De-ShanLi.Recombinantmurinefibroblastgrowthfactor21ameliorateobesity-relatedinflammationinmonosodiumglutamate-inducedobesityrats.Endocrine,2014(ImpactFactor:3.527)24.Fu-LiangBai,Yin-HangYu,HuiTian,Gui-PingRen,HuiWang,BingZhou,Xiao-HuiHan,Qing-ZhongYu&De-ShanLi.GeneticallyengineeredNewcastlediseasevirusexpressinginterleukin-2andTNF-relatedapoptosis-inducingligandforcancertherapy.CancerBiology&Therapy.2014,15(9):1226-1238(ImpactFactor:3.63)25.XuL,ZhangY,WangQ,ZhaoJ,LiuM,GuoM,JiangY,CaoH,LiQ,RenG,LiD.Bi-specificantibodieswithhighantigen-bindingaffinityidentifiedbyflowcytometry.IntImmunopharmacol.2014,24(2):463-473(ImpactFactor:2.711)26.X.Ye,J.Qi,Y.Wu,D.Yu,P.Xu,S.Li,S.Zhu,Q.Wu,G.Ren,D.Li.ComparisonofPEGylatedFGF-21withinsulinglargineforlong-lastinghypoglycaemiceffectindb/dbmice.Diabetes&Metabolism.2015,41(1):82-90(ImpactFactor:2.845)27.F.L.Bai,H.Tian,Q.Z.Yu,G.P.Ren,andD.S.Li.ExpressingForeignGenesbyNewcastleDiseaseVirusforCancerTherapy.MolecularBiology.2015,49(2):171-178(ImpactFactor:0.74)28.Si-mingLi,Wen-feiWang,Li-hongZhou,LeiMa,YingAn,Wen-juanXu,Tian-heLi,Yin-hangYu,De-shanLi,YanLiu.Fibroblastgrowthfactor21expressionsinwhitebloodcellsandseraofpatientswithgestationaldiabetesmellitusduringgestationandpostpartum.Endocrine,2014,May17(ImpactFactor:3.527)29.Li-MingXu,Tian-HeLi,BingZhou,MoGuo,MiaoLiu,Jing-ZhuangZhao,Hong-WeiCao,De-ShanLi.scFvantibodiesagainstinfectiousbursaldiseasevirusisolatedfromacombinatorialantibodylibrarybyflowcytometry.BiotechnologyLetters.2014,36,(5):1029-1035(ImpactFactor:1.736)30.Wen-feiWang,LeiMa,Ming-yaoLiu,Ting-tingZhao,TongZhang,Yong-biYang,Hong-xueCao,Xiao-huiHan,De-shanLi.Anovelfunctionforfibroblastgrowthfactor21:stimulationofNADPHoxidase-dependentROSgeneration.Endocrine.2015,49:385-395(ImpactFactor:3.527)31.WenfeiWang,NanZhang,TingtingZhao,MingyaoLiu,TongZhang&DeshanLi.InhibitionofTumorGrowthbyPolyarginine-FusedMutantCytosineDeaminase.AppliedBiochemistryandBiotechnology,2015,175(3):1633-43(ImpactFactor:1.687)32.ZhenyuZhang,WeiZhao,DeshanLi,JinlongYang,LaszloZsakandQingzhongYu.DevelopmentofaNewcastlediseasevirusvectorexpressingaforeigngenethroughaninternalribosomalentrysiteprovidesdirectproofforasequentialtranscriptionmechanism.JournalofGeneralVirology,2015,96,2028–2035(ImpactFactor:3.183)33.PengfeiXu,YingjieZhang,YunyeLiu,QingyanYuan,LiyingSong,MingyaoLiu,ZhihangLiu,YongbiYang,JunyanLi,DeshanLi,GuipingRen.Fibroblastgrowthfactor21attenuateshepaticfibrogenesisthroughTGF-β/smad2/3andNF-κBsignalingpathways.ToxicologyandAppliedPharmacology,290(2016)43-53(ImpactFactor:3.705)34.DanYu,XianlongYe,QiangWu,ShujieLi,YongbiYang,JinjiaoHe,YunyeLiu,XiaoyuZhang,QingyanYuan,MingyaoLiu,DeshanLi,GuipingRen.InsulinsensitizesFGF21inglucoseandlipidmetabolismsviaactivatingcommonAKTpathway.Endocrine.2015Nov25(ImpactFactor:3.878)教材：1、基因工程制药，主编，高等学校制药工程专业规划教材，化学工业出版社，2010